MetLife reports second-quarter results on June 16 against a backdrop of unusual momentum: the stock has climbed 13% over the past month to $88.84, and the Street has spent the last several weeks upgrading its view of the insurer's earnings power.
The analyst picture is the most striking element of this setup. Targets have moved sharply higher across the board — Morgan Stanley raised to $93, JP Morgan lifted to $96, Wells Fargo moved to $95, and Keefe Bruyette pushed to $98 — all in the weeks since the Q1 print beat expectations. The mean price target now sits at $92, which is just below where the stock already trades, meaning the rally has largely closed the gap that bulls were pointing to a month ago. One note of caution: Piper Sandler maintained a Neutral rating and raised its target to only $86, still below the current price. With the consensus rated "hold" and five analysts at that level against just one underperform, the Street's message is broadly constructive but not aggressively bullish — and the stock has moved so fast that upside to consensus targets is now thin.
Options positioning tells a mildly defensive story heading into the print. The put/call ratio is running at 1.36, modestly above its 20-day average of 1.30, placing it about one standard deviation above recent norms. That's not an extreme reading — the 52-week high was 1.81 — but it does suggest investors are adding slightly more downside protection than usual, even as the broader tone remains optimistic. Borrow conditions offer no drama at all: availability is extremely loose at over 3,200% of short interest, and the cost to borrow is a negligible 0.45%. Short interest itself, at 2.2% of float, rose roughly 8% on the week but remains categorically low. The lending market gives no signal of any meaningful bearish conviction.
Past earnings reactions have been muted and skewed negative. In two of the last three quarterly prints, the stock slipped 1-3% on the day and extended losses modestly over the following five sessions. The one exception was a Q4 release in April where the stock gained 1.6% on the day before fading. None of these moves were large, suggesting MetLife typically generates little post-earnings volatility — a dynamic that may be tested this time given the 13% run-up into the print and a 5% weekly gain that outpaced close peers PRU (+3.1%) and RGA (+4.1%), with only LNC (+7.5%) keeping pace.
The June 16 report will test whether MetLife's operating momentum — particularly in group benefits and the interest-rate tailwind feeding its general account — is strong enough to justify a stock that has already rallied past the Street's average price target.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
